RESEARCH-USE BIOSIMILAR ANTIBODY
Idarucizumab
Antibody fragment · IgG1
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
TARGETDabigatran
YAntibody fragment
CATALOGSC-BS-486
CATALOG NUMBERSC-BS-486
MOLECULAR WEIGHTLot-specific
PRODUCT FORMATAntibody fragment
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
Idarucizumab is a recombinant research-use antibody directed against Dabigatran.